Use of Oxalis or its extracts in the preparation of medicines for the prevention and / or treatment of infectious serositis in poultry

Abstract

This invention relates to the use of Oxalis corniculata or its extracts in the preparation of remedies for the prevention and / or treatment of infectious serositis and inflammatory diseases in poultry. This invention is the first to discover and experimentally demonstrate that Oxalis corniculata or its extracts can effectively prevent and treat inflammatory diseases in poultry, exhibiting more significant effects than other common anti-inflammatory traditional Chinese medicines; and can effectively prevent and treat infectious serositis in poultry (e.g., duck infectious serositis caused by Riemerella anatipestifer infection), thus showing promise as a therapeutic agent for inflammatory diseases and infectious serositis in poultry, with great application prospects and value.

Description

TECHNICAL FIELD

[0001] The present application relates to the technical field of biological medicine, in particular to the use of Oxalis corniculata L. or its extract in the preparation of a medicine for preventing and / or treating infectious serositis of poultry and a medicine for preventing and / or treating inflammatory diseases of poultry. BACKGROUND

[0002] Duck infectious serositis is a contact, acute or chronic, septicemic infectious disease caused by duck Riemerella anatipestifer in various poultry and wild birds such as ducks and geese, mainly affecting small ducks of 1-8 weeks old. The clinical symptoms include eye and nose secretions, green diarrhea, ataxia and convulsions, and chronic cases may have neurological symptoms. The lesion characteristics include fibrinous pericarditis, perihilar inflammation, air sac inflammation, caseous salpingitis, arthritis and paralysis. Duck infectious serositis is a common disease in the front line of breeding and is one of the main infectious diseases that endanger the duck breeding industry, often causing serious economic losses. In duck breeding production, the phenomenon of excessive use of antibiotics often occurs, and drug resistance is very common in many areas. With the increasing problem of drug-resistant strains, the demand for disease prevention and control is also increasing.

[0003] Duck infectious serositis can cause pericarditis and other inflammatory phenomena. With the increasing problem of clinical drug resistance in veterinary drugs, pure traditional Chinese medicine products are one of the solutions and have a broader application space. Finding traditional Chinese medicinal materials with good prevention and treatment effects for such diseases is an urgent need in the industry.

[0004] There are many traditional Chinese medicinal materials with antibacterial and anti-inflammatory effects. Finding traditional Chinese medicinal materials that can play a significant role in poultry breeding is a key work that veterinary drug research and development has been seeking to break through. Due to the differences in physiological functions between mammals and poultry, medicinal materials that have good effects in mammals may not have the same effects in poultry diseases, especially in group administration of poultry. Many personalized administration schemes also cannot achieve good effects in poultry breeding. Therefore, finding anti-inflammatory drugs for poultry is an urgent need for drug development.

[0005] Oxalis corniculata L. is a perennial herb with slender rhizomes, weak stems, and often brown, creeping or oblique, and many branches covered with soft hair. Oxalis corniculata L. tastes sour, has three small leaves, hence the name Oxalis corniculata L., sour grass, sour grass, sour grass, three-leafed sour grass, etc. It has the functions of clearing heat and dampness, cooling blood and removing blood stasis, and detoxifying and reducing swelling. It is used to treat damp-heat diarrhea, dysentery, jaundice, stranguria, leukorrhagia, hematemesis, epistaxis, hematuria, irregular menstruation, contusion and injury, sore throat, carbuncle, furuncle, erysipelas, eczema, scabies, hemorrhoids, measles, and scalding injury. In addition, Oxalis corniculata L. has the effect of clearing the heart and calming the mind, and can be used with pine needles and jujube to treat insomnia, dreaminess, and forgetfulness caused by heart heat. SUMMARY

[0006] Invention objectives

[0007] In view of the defects or needs in the prior art, the purpose of the present application is to use Oxalis corniculata or its extract in the preparation of a medicament for preventing and / or treating infectious serositis of poultry, and a medicament for preventing and / or treating inflammatory diseases of poultry.

[0008] Solution

[0009] To achieve the above-mentioned purpose, the present application adopts the following technical solutions:

[0010] In a first aspect, the present application provides the use of Oxalis corniculata or its extract in the preparation of a medicament for preventing and / or treating infectious serositis of poultry.

[0011] In a feasible embodiment of the above-mentioned use, the infectious serositis of poultry is selected from duck infectious serositis, goose infectious serositis and chicken infectious serositis.

[0012] Preferably, the infectious serositis of poultry is duck infectious serositis.

[0013] Further preferably, the duck infectious serositis is caused by Riemerella anatipestifer.

[0014] In the above-mentioned use, feasibly, the treatment of infectious serositis of poultry includes one or more of the following:

[0015] (1) delaying the progression rate of infectious serositis of poultry;

[0016] (2) improving the symptoms caused by infectious serositis of poultry, including improving pericarditis, perhepatitis, air sacculitis, caseous salpingitis, arthritis and paralysis caused by infectious serositis of poultry.

[0017] In a second aspect, the present application provides the use of Oxalis corniculata or its extract in the preparation of a medicament for preventing and / or treating infectious serositis of poultry.

[0018] For the above-mentioned use of the two aspects, feasibly, the extract of Oxalis corniculata is a water extract of Oxalis corniculata.

[0019] In a preferred specific embodiment, the water extract of Oxalis corniculata is prepared by the following method:

[0020] S1: Oxalis corniculata is decocted with water to extract, and the extract is filtered;

[0021] S2: the above-mentioned decoction and filtration procedure is repeated for several times;

[0022] S3: the filtrates obtained in step S2 are combined and concentrated, and the water extract of Oxalis corniculata is obtained.

[0023] Preferably, in step S1, the Oxalis corniculata L. powder is decocted and extracted with 10-15 times the amount of water; the "times" here refers to the multiple of the mass, for example, 1 kg of medicinal material, plus 10 kg of water, which is 10 times the amount of water;

[0024] Preferably, in step S1, the decoction time is 1-2 hours each time;

[0025] Preferably, in step S2, the decoction and filtration procedure is repeated 2-3 times;

[0026] Preferably, in step S3, the concentration is reduced pressure concentration, preferably to a crude drug content of 0.3-2 g / mL, preferably 0.5-1 g / mL; the "crude drug content" here is used to describe the relationship between the mass of the original medicinal material and the volume of the concentrated liquid obtained after extraction and concentration, specifically referring to the mass of the original medicinal material contained in a unit volume of concentrated liquid; for example, a crude drug content of 1 g / ml refers to the crude drug content of 1000 ml of concentrated liquid obtained by extracting 1000 g of medicinal material and concentrating to 1000 ml.

[0027] For the above two aspects of use, as a preferred, the medicine comprises a prophylactically and / or therapeutically effective amount of Oxalis corniculata L. or its extract, and optionally, a veterinary acceptable carrier and / or excipient.

[0028] Feasibly, the medicine is a medicine with the Oxalis corniculata L. or its extract as the only active ingredient, or a medicine composition with it as one of the active ingredients.

[0029] Feasibly, the administration mode of the medicine is oral, including but not limited to water administration and feed administration.

[0030] Preferably, the administration mode of the medicine is oral, including feed administration, water administration or direct oral administration.

[0031] Further feasibly, the medicine can also be prepared as an oral preparation, for example, oral solution, suspension, tablet, capsule, etc.

[0032] In a third aspect, the present application provides a method for preventing and / or treating infectious serositis of poultry, the method comprising: administering a prophylactically and / or therapeutically effective amount of Oxalis corniculata L. or its extract to poultry in need thereof.

[0033] In a fourth aspect, the present application provides a method for preventing and / or treating inflammatory diseases of poultry, the method comprising: administering a prophylactically and / or therapeutically effective amount of Oxalis corniculata L. or its extract to poultry in need thereof.

[0034] The term "effective amount" means the amount or dose of active ingredients, administered to a diseased poultry, either singly or in multiple doses, to provide the intended effect on the diagnosed or treated diseased poultry. The effective amount can be determined by a veterinarian involved in the diagnosis as a person skilled in the art by known techniques and observations obtained in similar situations. In determining the effective amount or dose of the active ingredients to be administered, the veterinarian involved in the diagnosis should consider various factors, including but not limited to: the extent or severity of the disease; the mode of administration; and other relevant situations.

[0035] Advantages

[0036] The inventors of the present application have found, through a large number of screenings, that Oxalis corniculata or its extract has a very good effect in the prevention and treatment of infectious serositis of poultry and inflammatory diseases of poultry, and thus provided the use of Oxalis corniculata or its extract in the preparation of a medicine for preventing and / or treating infectious serositis of poultry and inflammatory diseases of poultry. The inventors have confirmed through experiments that Oxalis corniculata or its extract can prevent and treat inflammatory diseases of poultry, and has a more outstanding effect than other common anti-inflammatory traditional Chinese medicines; and Oxalis corniculata or its extract can effectively prevent and treat infectious serositis of poultry (e.g., duck infectious serositis caused by duck plague Riemerella anatipestifer infection), and specifically can significantly reduce the mortality rate and the rate of liver and heart with a core of poultry caused by infectious serositis of poultry. BRIEF DESCRIPTION OF DRAWINGS

[0037] One or more embodiments are illustrated by way of example in the figures that constitute a part of this patent document. The illustrative examples set forth in the figures are not to be construed as limiting the embodiments. The term "exemplary" as used herein means "serving as an example, instance, or illustration." Any implementation described herein as "exemplary" is not necessarily to be construed as preferred or advantageous over other implementations.

[0038] Figure 1 The liver dissection results of the blank control group (A) and the duck infectious serositis model group (B) are shown. DETAILED DESCRIPTION

[0039] In order to make the objects, technical solutions and advantages of the present application clearer, the technical solutions of the present application will be described clearly and completely below in conjunction with the embodiments. Obviously, the described embodiments are part of the embodiments of the present application, rather than all the embodiments. Based on the embodiments in the present application, all other embodiments obtained by a person of ordinary skill in the art without any creative labor fall within the protection scope of the present application.

[0040] In addition, for a better understanding of the present application, a number of specific details are set forth in the following detailed description. Those skilled in the art will understand, however, that the application can be practiced without certain of the specific details set forth in the detailed description. In some instances, well-known pre-materials, components, methods, etc. have not been described in detail in order to avoid obscuring the present application.

[0041] Unless otherwise defined, all terms (including technical and scientific terms) used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this application belongs. It will be further understood that terms, such as those defined in commonly used dictionaries, should be interpreted as having a meaning that is consistent with their meaning in the context of the relevant art and the present disclosure, and will not be interpreted in an overly literal sense unless expressly so defined herein.

[0042] The present application is further explained by the following examples.

[0043] In the following examples, each raw material is a commercially available product unless otherwise specified.

[0044] I. Preparation of each Chinese medicine water extract

[0045] In the following examples and comparative examples, the Herba Galiums, Sophora flavescens, Phellodendri, Honeysuckle, and Isatidis were purchased from Agou City Jufu Chinese Herbal Medicine Co., Ltd., and all met the standards of the Pharmacopoeia.

[0046] Example 1: Preparation of Herba Galiums water extract

[0047] Herba Galiums 100 parts, 10 times the amount of water decoction, decoction 2 times, 1 hour each time, combined filtrate, reduced pressure concentration to 1 g / mL of crude drug content.

[0048] Example 2: Preparation of Herba Galiums water extract

[0049] Herba Galiums 100 parts, 12 times the amount of water decoction, decoction 3 times, 1.5 hours each time, combined filtrate, reduced pressure concentration to 1 g / mL of crude drug content.

[0050] Example 3: Preparation of Herba Galiums water extract

[0051] Herba Galiums 100 parts, 10 times the amount of water decoction, decoction 2 times, 1 hour each time, combined filtrate, reduced pressure concentration to 0.5 g / mL of crude drug content.

[0052] Example 4: Preparation of Herba Galiums water extract

[0053] Herba Galiums 100 parts, 10 times the amount of water decoction, decoction 2 times, 1 hour each time, combined filtrate, reduced pressure concentration to 0.2 g / mL of crude drug content.

[0054] Comparative Example 1: Preparation of Sophora flavescens water extract

[0055] Sophora flavescens 100 parts, add 10 times the amount of water decoction, decoction 2 times, 1 hour each time, combined filtrate, reduced pressure concentration to the content of crude drug is 1 g / mL.

[0056] Preparation of water extract of Phellodendri chinensis bark

[0057] Phellodendri chinensis bark 100 parts, add 10 times the amount of water decoction, decoction 2 times, 1 hour each time, combined filtrate, reduced pressure concentration to the content of crude drug is 1 g / mL.

[0058] Preparation of water extract of Lonicera japonica

[0059] Lonicera japonica 100 parts, add 10 times the amount of water decoction, decoction 2 times, 1 hour each time, combined filtrate, reduced pressure concentration to the content of crude drug is 1 g / mL.

[0060] Preparation of water extract of Radix isatidis

[0061] Radix isatidis 100 parts, add 10 times the amount of water decoction, decoction 2 times, 1 hour each time, combined filtrate, reduced pressure concentration to the content of crude drug is 1 g / mL.

[0062] In the above preparation examples, the "times" refers to the multiple of the mass, as described above; for example, 1 kg of medicinal materials, add 10 kg of water, referred to as 10 times the amount of water. The "content of crude drug" refers to the mass of the original medicinal materials contained in the unit volume of concentrated liquid, as described above; for example, the content of crude drug of 1 g / ml refers to: 1000 g of medicinal materials is extracted and concentrated to 1000 ml to form 1000 ml of concentrated liquid.

[0063] II. Anti-inflammatory effect experiment

[0064] 1. Experimental materials

[0065] 1.1 Animals

[0066] Kunming mice, 4-5 weeks old, 20±2 g, male and female; purchased from Beijing Vito Lihua Co., Ltd., ordinary environment feeding, free feeding, water, adaptive feeding for 1 week before experiment.

[0067] 1.2 Drugs

[0068] Oxalis corniculata extract, prepared in Example 1, crude drug content 1 g / mL;

[0069] Sophora flavescens extract, prepared in Comparative Example 1, crude drug content 1 g / mL;

[0070] Phellodendri chinensis bark extract, prepared in Comparative Example 2, crude drug content 1 g / mL;

[0071] Lonicera japonica extract, prepared in Comparative Example 3, crude drug content 1 g / mL;

[0072] Radix isatidis extract, prepared in accordance with Example 4, crude drug content 1 g / mL;

[0073] Aspirin effervescent tablets, purchased from AstraZeneca Pharmaceuticals Co., Ltd., specification: 0.5 g / tablet;

[0074] Xylene, commonly commercially available reagent.

[0075] 1.3 Instruments

[0076] BT224S electronic analytical balance.

[0077] 2. Anti-inflammatory effect experiment

[0078] 2.1 Experimental method

[0079] Take 70 Kunming mice with similar body weight, male, group and dosing as shown in Table 1 below, 10 mice per group, continuous dosing for 3 days, 1 hour after the last dosing, apply 20 μL of xylene to the right ear of the animal, and do not treat the left ear, to make an inflammation model mouse (see Experimental Animals and Experimental Animal Models, Du Li Jun et al., 2012, pp. 325-326). 20 min later, decapitate the animals in each group, carefully cut off the ears along the auricle, and use a 6 mm diameter puncher to punch a round ear piece at the same site, weigh on an analytical balance, and the weight of the right ear minus the weight of the left ear is the degree of swelling, which is calculated by the following formula to calculate the swelling inhibition rate, as an indicator of the degree of inflammation.

[0080] Swelling inhibition rate = (model control group swelling amount - experimental group swelling amount) / model control group swelling amount x 100%.

[0081] Table 1. Experimental grouping

[0082]

[0083] 2.2 Data analysis

[0084] Use PASW Statistics 18.0 software to statistically analyze the experimental data, P < 0.05 indicates significant difference, P < 0.01 indicates extremely significant difference.

[0085] 2.3 Experimental results

[0086] The anti-inflammatory effect determination results are shown in Table 2 below.

[0087] Table 2. Effect of each sample on xylene-induced mouse auricle swelling

[0088]

[0089] Note: compared with the model control group, "*" indicates P < 0.05

[0090] As shown in Table 2, compared with the model control group, Example 1, Comparative Example 1 and Comparative Example 3 have obvious inhibitory effect on the mouse ear swelling caused by xylene, and the difference is significant (P<0.05), which shows that Example 1 (water extract of Galium verum L.), Comparative Example 1 (water extract of Sophora flavescens) and Comparative Example 3 (water extract of Lonicera japonica) have obvious anti-inflammatory effect.

[0091] III. Prevention and treatment effect on duck infectious serositis

[0092] 1. Experimental materials

[0093] 1.1 Experimental animals and strains

[0094] Experimental animals: 1-day-old ducklings (non-immunized), purchased from Tianjin Jizhou District Bao Hui Poultry Hatchery, and raised to 2 weeks old for experiments; experimental ducks were raised in standard duck houses with free access to food and water, and fed with antibiotic-free complete feed during the entire experimental process.

[0095] Experimental strains: duck Riemerella anatipestifer, from Shengtai Research Institute of Toxic Strains Center. The strain is a conventional strain and is available to the public, for example, it can be isolated from sick ducks.

[0096] 1.2 Experimental drugs

[0097] Each traditional Chinese medicine water extract prepared in Examples 1-4 and Comparative Examples 1-4.

[0098] 1.3 Experimental methods and grouping

[0099] 1.3.1 Preparation of duck Riemerella anatipestifer bacterial solution for preparing duck infectious serositis animal model and control standards

[0100] Sterilized tryptone soya agar medium (TSA) and tryptone soya broth medium (TSB) were prepared respectively, and 10% calf serum was added as the culture medium for duck Riemerella anatipestifer.

[0101] The freeze-dried duck Riemerella anatipestifer strain base seed was streaked onto a TSA plate, and cultured at 37°C for 16-24 hours under 5-10% CO2 conditions. Several typical colonies were picked and inoculated into 100-200 ml of TSB culture medium, and cultured at 37°C for 12-24 hours to harvest the bacterial solution. The bacterial solution was divided into high-pressure sterilized 10 ml test tubes, 5-7 ml per 10 ml test tube.

[0102] Viable bacterial count: the viable bacterial content in the bacterial solution should not be less than 8×10 6 CFU / 0.2ml.

[0103] Storage and shelf life: stored below -70°C, and the shelf life should not exceed 7 days.

[0104] 1.3.2 Preparation of duck infectious serositis animal model

[0105] In the bacterial challenge, the duck Riemerella anatipestifer bacteria solution prepared in the above 1.3.1 section was injected into each duckling at 0.2 mL to prepare the duck infectious serositis model duck; specifically, the neck subcutaneous injection was used, one person fixed the duckling, one person sucked the prepared bacteria solution in advance, pinched the skin of the neck of the duckling, and injected 0.2 ml of bacteria solution into the triangular area formed by the neck and the skin, and then placed it in the original cage after injection, and gave oral administration every day, and recorded the experimental conditions of each group.

[0106] 1.3.3 Drug efficacy experiment

[0107] In addition to the model control group and the blank control group, the rest of the groups were given drugs 2 days before modeling, and the drug administration mode was oral administration to test the corresponding drugs of each administration group; the model group was given drinking water, and as described above, on the day of bacterial challenge, each group was modeled by injecting bacteria solution subcutaneously in the neck. Each administration group continued to administer drugs for 6 days, and the death, clinical symptoms, mental state, feces color, and food and water intake of each group were observed during the experiment. On the 7th day, the remaining ducks in each group were dissected, and the pericardial and liver conditions of the ducks in each group were observed and compared (the dead ducks during the experiment were counted according to the pericardial and liver conditions). Each group contained two parallel groups, each with 13 ducks, i.e., each group contained 26 ducks.

[0108] The experimental grouping is shown in Table 3 below.

[0109] Table 3. Experimental grouping

[0110]

[0111]

[0112] 1.3.4 Observation index

[0113] (1) Clinical symptoms

[0114] Ducks with the disease will have varying degrees of yellowish or greenish watery diarrhea, depression, nasal discharge of serous or mucous secretions, and "eye circles" phenomenon, decreased appetite, head and wing retraction, fluffy feathers, weak legs, and difficulty walking, and as the disease worsens, some will show clinical symptoms such as head and neck extension, arching of the horns, convulsions, and soiled feathers around the anus.

[0115] During the experiment, the mental state, behavior, food and water intake, feces condition, and number of dead ducks per day in each group were observed and recorded.

[0116] (2) Infection and disease

[0117] The healthy control group was lively, and the behavior and appetite were normal. In contrast, the ducklings inoculated with bacteria showed obvious clinical symptoms such as depression, squatting, and loss of appetite.

[0118] (3) Infection mortality

[0119] Determination of duck Riemerella anatipestifer infection death:

[0120] First, determine whether it is duck Riemerella anatipestifer infection death according to the pathological changes of each dead duck. If it cannot be determined according to the pathological changes, then isolate the strain to determine.

[0121] Specifically, during the experiment, the duck suddenly died after being inoculated with duck Riemerella anatipestifer or showed obvious clinical symptoms of duck Riemerella anatipestifer, and autopsy showed that most of the internal organs had E. coli lesions. For those without typical clinical symptoms or pathological changes, further isolation of strains from the liver, heart blood or air sacs was performed to determine whether the same duck Riemerella anatipestifer could be isolated as the inoculated bacteria. If so, it was determined to be an infection death.

[0122] The calculation formula of infection mortality is as follows:

[0123] Infection mortality (%) = number of deaths in the group / number of experimental ducks in the group x 100%.

[0124] (4) Pericardial and hepatization rate

[0125] Autopsy of sick ducks showed a thin layer of cellulose covering the surface of the liver, and the liver was swollen and brittle. Pericardial effusion, with cellulose exudate, had a large amount of cellulose villus attached to the epicardium with a long course of disease, the spleen was enlarged and had a mottled appearance, and the meninges were congestive and edematous. By checking the lesion condition of the autopsied duck, there was cellulose pericarditis around the heart, some with caseous exudate, the liver capsule was white and turbid, with cellulose attachment, and sometimes white necrotic spots could be seen. If cellulose attachment phenomenon occurs in any part of the heart or liver, it is considered as pericardial and hepatization, and the dead duck is also counted as pericardial and hepatization.

[0126] The calculation formula of pericardial and hepatization rate is as follows:

[0127] Pericardial and hepatization rate = number of pericardial and hepatization ducks in the group / total number of ducks in the group x 100%.

[0128] 1.3.5 Experimental results

[0129] (1) Clinical symptoms

[0130] After being challenged with Riemerella anatipestifer, ducks experienced a sharp decline in feed intake. The infected ducks exhibited varying degrees of pale green or grayish-white watery diarrhea, lethargy, serous or viscous discharge from the eyes and nose, large eye rings, decreased appetite, drooping head and wings, ruffled feathers, weak legs and difficulty walking, and some ducklings exhibited head and neck tilting backward, opisthotonus, and convulsions. Except for the control group, ducklings died in all groups.

[0131] (2) Pathological changes

[0132] Figure 1 Figures A and B in the diagram show the necropsy results of surviving ducks from the blank control group and the model control group, respectively. Figure 1 It can be seen that, compared with the blank control group, the ducklings in the model control group showed increased pericardial fluid and fibrinous exudate covering the epicardium after inoculation with Riemerella anatipestifer. Furthermore, in those with a longer disease course, the pericardium adhered to the epicardium, the exudate on the liver surface was uniform and thin, and the liver appeared as pale yellow or grayish-white clumps. These results fully demonstrate the successful establishment of the duck infectious serositis animal model.

[0133] (3) Infection mortality rate and pericardial and perihepatic rates

[0134] The number of ducks that died in each group during the experiment is shown in Table 4 below.

[0135] The infection mortality rate and pericarditis / hepatitis rate of each experimental group of ducks are shown in Table 5 below. Statistical analysis of the data from each group was performed using the data analysis method described in section 2.2 of "II. Anti-inflammatory Effect Experiment" above. The significance of the differences between the groups is marked in Table 5.

[0136] Table 4. Number of ducks that died in each group during the experiment (in birds)

[0137]

[0138] Table 5. Mortality and pericardial and perihepatic tract infection rates in each experimental group of ducks.

[0139]

[0140] Note: Different letters indicate that there is a significant difference between the two.

[0141] As shown in Tables 4 and 5, compared with the model control group, the infection mortality rate and pericarditis / hepatitis rates of the Oxalis corniculata water extract treatment groups in Examples 1-4 were significantly reduced, while there were no significant differences in the other Chinese herbal medicine water extract treatment groups in Examples 1-4. This indicates that Oxalis corniculata water extract can significantly reduce the mortality rate and pericarditis / hepatitis rates caused by Riemerella anatipestifer infection, thus having a significant therapeutic effect on duck infectious serositis caused by Riemerella anatipestifer.

[0142] It should be pointed out finally that the above embodiments are only used to illustrate the technical solutions of the present application, but not to limit the same; and although the present application has been described in detail with reference to the foregoing embodiments, it should be appreciated by those skilled in the art that the technical solutions recorded in the foregoing embodiments can be modified, or some technical features thereof can be replaced equivalently; and these modifications or replacements do not make the essence of the corresponding technical solutions deviate from the spirit and scope of the technical solutions of the embodiments of the present application.

Claims

1. Use of a plant of Oxalidaceae or an extract thereof in the preparation of a medicament for preventing and / or treating infectious serositis of poultry.

2. Use according to claim 1, characterized in that, The infectious serositis of poultry is selected from the group consisting of infectious serositis of duck, infectious serositis of goose and infectious serositis of chicken.

3. Use according to claim 1, characterized in that, The infectious serositis of poultry is infectious serositis of duck.

4. Use according to claim 3, characterized in that, The infectious serositis of duck is caused by Riemerella anatipestifer.

5. Use according to any one of claims 1 to 4, characterized in that, The extract of Oxalidaceae is a water extract of Oxalidaceae.

6. Use according to claim 5, characterized in that, The water extract of Oxalidaceae is prepared by the following method: S1: decocting and extracting Oxalidaceae with water, and filtering the extract; S2: repeating the above decocting and filtering procedure for several times; S3: combining the filtrates obtained in step S2, and concentrating, to obtain the water extract of Oxalidaceae.

7. Use according to claim 6, characterized in that, In step S1, 10-15 times of water is used to decoct and extract the powder of Oxalidaceae; and / or, in step S1, the decocting time is 1-2 hours each time; and / or, in step S2, the decocting and filtering procedure is repeated for 2-3 times; and / or, in step S3, the concentration is reduced pressure concentration, and the concentration is performed until the content of crude drug is 0.3-2 g / mL.

8. Use according to claim 7, characterized in that, In step S3, the concentration is reduced pressure concentration, and the concentration is performed until the content of crude drug is 0.5-1 g / mL.

9. Use according to any one of claims 1 to 4, characterized in that, The medicament is a medicament with the plant of Oxalidaceae or the extract thereof as the only active ingredient, or a pharmaceutical composition with the plant of Oxalidaceae or the extract thereof as one of the active ingredients.

10. Use according to any one of claims 1 to 4, characterized in that, The administration of the medicament is oral administration.

11. Use according to claim 10, characterized in that, The oral administration includes mixing, drinking water administration or direct oral administration; and / or, the medicament is prepared in the form of oral preparation.

12. Use according to claim 11, characterized in that, The oral preparation is selected from the group consisting of oral solution, suspension, tablet and capsule.

Images